241 related articles for article (PubMed ID: 33588870)
21. Single administration of avelumab induced a complete response in thyroid transcription factor 1-positive combined Merkel cell carcinoma.
Kanemaru H; Fukushima S; Mizukami Y; Sawamura S; Nakamura K; Honda N; Makino K; Kajihara I; Aoi J; Makino T; Kawasaki T; Kudou E; Jhono M; Ito T; Arima N; Ihn H
J Dermatol; 2020 Nov; 47(11):1317-1321. PubMed ID: 32794263
[TBL] [Abstract][Full Text] [Related]
22. Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma.
Joseph J; Zobniw C; Davis J; Anderson J; Trinh VA
Ann Pharmacother; 2018 Sep; 52(9):928-935. PubMed ID: 29616562
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of avelumab versus chemotherapy in Merkel cell carcinoma: innovative use of patient insights.
Bharmal M; Marrel A; Hennessy M; Fofana F; Lambert J; Arnould B
J Comp Eff Res; 2018 Sep; 7(9):881-890. PubMed ID: 30107762
[TBL] [Abstract][Full Text] [Related]
24. Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma.
Teets A; Pham L; Tran EL; Hochmuth L; Deshmukh R
Crit Rev Immunol; 2018; 38(3):159-206. PubMed ID: 30004857
[TBL] [Abstract][Full Text] [Related]
25. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.
Barkdull S; Brownell I
Cancer Biol Ther; 2017 Dec; 18(12):937-939. PubMed ID: 29172995
[TBL] [Abstract][Full Text] [Related]
27. Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma.
Glutsch V; Kneitz H; Gesierich A; Goebeler M; Haferkamp S; Becker JC; Ugurel S; Schilling B
Cancer Immunol Immunother; 2021 Jul; 70(7):2087-2093. PubMed ID: 33439294
[TBL] [Abstract][Full Text] [Related]
28. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
Baker M; Cordes L; Brownell I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma.
Hu P; Dai HI; Bourdage J; Zhou D; Trang K; Kowalski K; Bello C; Hibma J; Khandelwal A; Cowan K; Dong J; Venkatakrishnan K; Gao W
Clin Transl Sci; 2024 Mar; 17(3):e13730. PubMed ID: 38411318
[TBL] [Abstract][Full Text] [Related]
30. Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe.
Fife K; Tétu P; Prabhakaran J; Lebbé C; Grignani G
Front Oncol; 2021; 11():672021. PubMed ID: 34123840
[TBL] [Abstract][Full Text] [Related]
31. Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.
Lanitis T; Proskorovsky I; Ambavane A; Hunger M; Zheng Y; Bharmal M; Phatak H
Adv Ther; 2019 Sep; 36(9):2327-2341. PubMed ID: 31350728
[TBL] [Abstract][Full Text] [Related]
32. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial.
Vaishampayan U; Schöffski P; Ravaud A; Borel C; Peguero J; Chaves J; Morris JC; Kotecki N; Smakal M; Zhou D; Guenther S; Bajars M; Gulley JL
J Immunother Cancer; 2019 Oct; 7(1):275. PubMed ID: 31651359
[TBL] [Abstract][Full Text] [Related]
33. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
[TBL] [Abstract][Full Text] [Related]
34. Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.
Grisic AM; Xiong W; Tanneau L; Jönsson S; Friberg LE; Karlsson MO; Dai H; Zheng J; Girard P; Khandelwal A
Clin Cancer Res; 2022 Apr; 28(7):1363-1371. PubMed ID: 34921021
[TBL] [Abstract][Full Text] [Related]
35. Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT-confirmed complete response.
Zijlker LP; Levy S; Wolters W; van Thienen JV; van Akkooi ACJ; Tesselaar MET
Cancer; 2024 Feb; 130(3):433-438. PubMed ID: 37788133
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study.
Verschraegen CF; Jerusalem G; McClay EF; Iannotti N; Redfern CH; Bennouna J; Chen FL; Kelly K; Mehnert J; Morris JC; Taylor M; Spigel D; Wang D; Grote HJ; Zhou D; Munshi N; Bajars M; Gulley JL
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32907924
[TBL] [Abstract][Full Text] [Related]
37. Avelumab and other recent advances in Merkel cell carcinoma.
Bommareddy PK; Kaufman HL
Future Oncol; 2017 Dec; 13(30):2771-2783. PubMed ID: 28976209
[TBL] [Abstract][Full Text] [Related]
38. Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma.
Torchio M; Cattaneo L; Milione M; Prinzi N; Corti F; Ungari M; Anichini A; Mortarini R; Occhini A; Bertino G; Maurichi A; Coppa J; Di Bartolomeo M; de Braud FG; Pusceddu S
Front Oncol; 2021; 11():628324. PubMed ID: 34221958
[TBL] [Abstract][Full Text] [Related]
39. Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma-A multicenter real-world experience in Israel.
Averbuch I; Stoff R; Miodovnik M; Fennig S; Bar-Sela G; Yakobson A; Daliot J; Asher N; Fenig E
Cancer Med; 2023 Jun; 12(11):12065-12070. PubMed ID: 37012213
[TBL] [Abstract][Full Text] [Related]
40. Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study.
Drusbosky L; Nangia C; Nguyen A; Szeto C; Newton Y; Spilman P; Reddy SB
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32913030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
